Wedbush Reiterates Outperform on AnaptysBio, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for AnaptysBio (NASDAQ:ANAB) and maintained a price target of $42.
September 26, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for AnaptysBio and maintained a price target of $42, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $42 price target by a reputable analyst suggests a positive outlook for AnaptysBio. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100